Margrethe Sørgaard joins the company’s cross-functional R&D team following Calluna’s launch, to oversee the strategic development of the company’s clinical programs in line with regulatory guidelines and safety requirements.

With over 25 years’ experience from different leading positions in clinical development and operation, medical affairs, and drug safety/pharmacovigilance, she will play a pivotal role in supporting the development of Calluna’s clinical programs including CAL101, the company’s lead product as it enters Phase IIa clinical development, the company states.

“We look forward to leveraging Margrethe’s expertise in all aspects of clinical development and clinical operations, to help ensure Calluna’s clinical programs run according to the company’s strategy, applicable legislation, regulations, and guidelines, while prioritizing patient safety,” says John Montana, Chief Executive Officer of Calluna Pharma.

Margrethe Sørgaard

Margrethe joins Calluna from BioInvent International where she was the Senior Director of Safety and PV, supporting product safety and assuring safety standards were compliant with global drug safety regulations. Prior to this, she was the VP and Head of Clinical Development at Circio Holding, and has previously gained experience in regulatory pre-and post-marketing processes and quality assurance, by serving as an EU Qualified Person for Pharmacovigilance (QPPV) while at Photocure, and Head of Unit for Safety Assessment and GCP/PhV inspector at the Norwegian Medicines Agency (NOMA).

She holds an M.Sc. in Biology (Physiology) from the University of Oslo.

Calluna’s groundbreaking approach in targeting upstream innate immune amplifiers has the potential to revolutionize treatment across a spectrum of diseases associated with chronic inflammation and fibrosis, improving patient outcomes, and fulfilling unmet medical needs.”

“I am thrilled to join Calluna’s team at such an exciting stage of the company’s development. Calluna’s groundbreaking approach in targeting upstream innate immune amplifiers has the potential to revolutionize treatment across a spectrum of diseases associated with chronic inflammation and fibrosis, improving patient outcomes, and fulfilling unmet medical needs. I look forward to becoming an integral part of the development of our clinical programs,” says Sørgaard.

Read a full interview and learn more about Sørgaard’s career and her experiences from leadership positions within the life science industry in our upcoming issue – out September 6th!